KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Operating Income: 2009-2025

Historic Operating Income for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -$160.2 million.

  • Ionis Pharmaceuticals' Operating Income fell 7.75% to -$160.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.0 million, marking a year-over-year increase of 24.93%. This contributed to the annual value of -$475.1 million for FY2024, which is 34.31% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Operating Income stood at -$160.2 million, which was down 214.57% from $139.8 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Operating Income ranged from a high of $220.6 million in Q4 2021 and a low of -$208.0 million during Q4 2022.
  • Moreover, its 3-year median value for Operating Income was -$114.1 million (2023), whereas its average is -$90.5 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Operating Income skyrocketed by 1,073.36% in 2021 and then tumbled by 1,710.21% in 2024.
  • Over the past 5 years, Ionis Pharmaceuticals' Operating Income (Quarterly) stood at $220.6 million in 2021, then plummeted by 194.30% to -$208.0 million in 2022, then surged by 97.06% to -$6.1 million in 2023, then slumped by 1,710.21% to -$110.8 million in 2024, then declined by 7.75% to -$160.2 million in 2025.
  • Its Operating Income was -$160.2 million in Q3 2025, compared to $139.8 million in Q2 2025 and -$146.9 million in Q1 2025.